Eurofins Scientific, a provider of bioanalytical tests has acquired of Beacon Discovery, a contractual research and drug discovery organization specializing in research on G protein-coupled receptors. Beacon Discovery integrates Eurofins Discovery, a leading CRO with a broad portfolio of validated in vitro pharmacology, ADMET, and chemistry services for integrated drug discovery solutions.

Dr. Gilles Martin, CEO of Eurofins, said, “Beacon Discovery strengthens expertise in GPCR targets, drug discovery and development experience in order to diversify our integrated service offering. This transaction once again demonstrates our commitment of Eurofins to provide the most comprehensive possible portfolio of laboratory services in the field of pharmacological discovery, which is currently experiencing a strong trend towards outsourcing.